Who are timolol maleate and dorzolamide hydrochloride's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/timolol-maleate-and-dorzolamide-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

timolol maleate and dorzolamide hydrochloride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

timolol maleate and dorzolamide hydrochloride (timolol maleate and dorzolamide hydrochloride) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-adrenergic antagonist and carbonic anhydrase inhibitor combination. Area: Ophthalmology.

marketed Beta-adrenergic antagonist and carbonic anhydrase inhibitor combination Beta-2 adrenergic receptor (timolol); carbonic anhydrase II (dorzolamide) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

timolol maleate and dorzolamide hydrochloride (timolol maleate and dorzolamide hydrochloride) — University of Florida. This combination reduces intraocular pressure by decreasing aqueous humor production (timolol via beta-adrenergic blockade) and increasing aqueous humor outflow (dorzolamide via carbonic anhydrase inhibition).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
timolol maleate and dorzolamide hydrochloride TARGET	timolol maleate and dorzolamide hydrochloride	University of Florida	marketed	Beta-adrenergic antagonist and carbonic anhydrase inhibitor combination	Beta-2 adrenergic receptor (timolol); carbonic anhydrase II (dorzolamide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-adrenergic antagonist and carbonic anhydrase inhibitor combination class)

University of Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). timolol maleate and dorzolamide hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/timolol-maleate-and-dorzolamide-hydrochloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab